DRMA
DRMA
NASDAQ · Biotechnology

Dermata Therapeutics Inc

$1.19
+0.05 (+4.39%)
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +3,158.8% upside
Low Target $26.82
Average Target $38.78
High Target $44.92
Current Price $1.19
Current
$1.19
Target
$38.78
$26.82 $38.78 avg $44.92
Scenario Analysis
Bear Case
$26.82
2,153.8%
Low target
Base Case
$38.78
+3,158.8%
Avg target
Bull Case
$44.92
+3,674.8%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$23.70
-95.0% from high
52-Week Low
$1.11
+7.2% from low
Target vs 52W High
$38.78
+63.6% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Buy 39 69% $257.58 +18.4%
AMGN
Amgen Inc
Hold 42 50% $190.87 -45.8%
GILD
Gilead Sciences Inc
Strong Buy 38 79% $362.68 +160.2%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 79% $438.34 -1.8%
REGN
Regeneron Pharmaceuticals
Strong Buy 36 75% $76.80 -90.1%
ALNY
Alnylam Pharmaceuticals Inc
Strong Buy 36 78% $102.31 -69.1%
INSM
Insmed Inc
Strong Buy 26 92% $143.40 -12.3%
NTRA
Natera Inc
Strong Buy 27 89% $142.91 -28.5%